The role of T3 on immune function in Graves' disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010459

Enrollment

Unknown

Registered

2017-01-17

Start date

2017-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves‘ disease

Interventions

A (Graves disease):T3

B (Graves disease):none

C (healthy population):T3

C (healthy population):none

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Conventional symptoms of hyperthyroidism associated with a typical enlarged goiter; 2. elevated levels of free T3, free T4 and depressed TSH level; 3. The test of thyroidal iodine-131 uptake was conducted to exclude the subacute thyroiditis when necessary.

Exclusion criteria

Exclusion criteria: 1. pregnant and lactating women; 2. patients combined with thyroid tumor or thyroiditis.

Design outcomes

Primary

Measure	Time frame
Thyroid function;	—

Secondary

Measure	Time frame
blood routine examination;routine urine test;liver function;	—

Countries

China

Contacts

Public ContactXiaomei Liu

Nanjing First Hospital, Nanjing Medical University

lxmxjtu@sina.com+86 15366110069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026